Author:
Tian Ye,Tao Xiaosha,Feng Yuanyuan,Yin Lihui,Ning Baoming
Reference27 articles.
1. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals;Wichitnithad;Saudi Pharm. J.,2023
2. The European Medicines Agency, Nitrosamine impurities in human medicinal products, Amsterdam, 2020. 〈https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf〉 (accessed 09 June 2020).
3. Ranitidine—investigations into the root cause for the presence of N-Nitroso-N,N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products;King;Org. Process Res. Dev.,2020
4. Thermodynamic study of thermal decomposition of ranitidine by HPTLC;Nowakowska;J. Liq. Chromatogr. Relat. Technol.,2012
5. U.S. Food and Drug Administration, FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. 〈https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market/〉, 2020 (accessed 10 April 2020).